Technical Analysis for GLYC - GlycoMimetics, Inc.

Grade Last Price % Change Price Change
grade B 23.59 8.46% 1.84
GLYC closed up 8.46 percent on Friday, January 19, 2018, on 2.3 times normal volume. The bulls were able to push the stock to a new 52-week high.
6 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Very Strong Up Up Up
See historical GLYC trend table...

Date Alert Name Type % Chg
Jan 19 New 52 Week Closing High Bullish 0.00%
Jan 19 Expansion Breakout Bullish Swing Setup 0.00%
Jan 19 Wide Range Bar Range Expansion 0.00%
Jan 19 New 52 Week High Strength 0.00%
Jan 19 Upper Bollinger Band Walk Strength 0.00%
Jan 19 Wide Bands Range Expansion 0.00%
Jan 19 Above Upper BB Strength 0.00%
Jan 19 Overbought Stochastic Strength 0.00%
Jan 19 Up 3 Days in a Row Strength 0.00%
Jan 19 Upper Bollinger Band Touch Strength 0.00%

Older signals for GLYC ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases. Its lead product includes GMI-1070, a glycomimetic drug candidate that acts as a pan-selectin antagonist has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The company is also developing GMI-1271, a specific E-selectin antagonist, which it plans to initiate a Phase I dose-escalation clinical trials in healthy volunteers to be used in combination with chemotherapy to treat acute myeloid leukemia and potentially other hematologic cancers. In addition, its drug candidates comprise GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Gaithersburg, Maryland.
Is GLYC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 25.2
52 Week Low 3.82
Average Volume 729,174
200-Day Moving Average 11.6838
50-Day Moving Average 15.6152
20-Day Moving Average 18.542
10-Day Moving Average 20.108
Average True Range 1.4149
ADX 52.22
+DI 47.4
-DI 9.39
Chandelier Exit (Long, 3 ATRs ) 20.9553
Chandelier Exit (Short, 3 ATRs ) 19.8147
Upper Bollinger Band 22.4376
Lower Bollinger Band 14.6464
Percent B (%b) 1.15
BandWidth 42.0192
MACD Line 1.6938
MACD Signal Line 1.3852
MACD Histogram 0.3086
Fundamentals Value
Market Cap 771.93 Million
Num Shares 32.7 Million
EPS -1.34
Price-to-Earnings (P/E) Ratio -17.60
Price-to-Sales 18873.21
Price-to-Book 3.02
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 28.39
Resistance 3 (R3) 28.39 26.80 27.59
Resistance 2 (R2) 26.80 25.57 26.80 27.32
Resistance 1 (R1) 25.19 24.82 26.00 25.19 27.06
Pivot Point 23.60 23.60 24.00 23.60 23.60
Support 1 (S1) 21.99 22.37 22.80 21.99 20.12
Support 2 (S2) 20.40 21.62 20.40 19.86
Support 3 (S3) 18.79 20.40 19.59
Support 4 (S4) 18.79